He just said 48 (IN A MONITOR POOL) under quarantine as I understand it no? ALL EMS Vehicles will be diverted to another hospital.
Now...what is going on with the 60 who lined up for the experimental 'VACCINE'..how are they? They supposedly received the 'VACCINE' on September 17/2014.
have all the 'Guinea Pigs' suddenly become symptomatic and been taken to the Texas Presbyterian Hospital for 'Observation'? I hear too many ..UUUH,UUUH,UUUH's...
~~~
First British volunteer injected with trial Ebola vaccine in Oxford...If vaccine tested on Ruth Atkins and other healthy volunteers is found to work, it will be fast-tracked for use in west Africa.
"Atkins is the first of 60 healthy people who will be vaccinated to find out whether the potential vaccine has any troublesome side effects. Studies involving animals have shown no ill effects
so far."
http://www.theguardian.com/society/...volunteer-injected-trial-ebola-vaccine-oxford
~~~~AND THEN HERE>>>
Embargoed for Release: Thursday, August 28, 2014, 9:30 a.m. EDT
NIH to Launch Human Safety Study of Ebola Vaccine Candidate
Trial is First in Series of Accelerated Safety Studies of Ebola Vaccines
**"The Phase 1 clinical trial, called VRC 207, will be led by principal investigator Julie E. Ledgerwood, D.O., chief of the VRC’s clinical trials program, and will be conducted among 20 healthy adults ages 18 to 50 years. Participants will be divided into two groups of 10 participants each. One group will receive an intramuscular injection of the NIAID/GSK experimental vaccine. The second group will receive a single injection of the same vaccine but at a higher dose."
**"Additional Phase 1 Tests of the
NIAID/GSK Vaccine
As part of the VRC 207 trial, NIAID will also test a version of the NIAID/GSK vaccine that contains genetic material from only the Zaire Ebola species. Hence, this vaccine is referred to as a monovalent vaccine. This portion of the Phase 1 safety study, which will also involve 20 healthy adults, is expected to begin in October at the NIH Clinical Center and potentially another U.S. location. Dr. Ledgerwood will also lead that effort. The VRC 207 clinical trial is being conducted based on expedited review and approval by the U.S. Food and Drug Administration."
~~~~
***"In parallel, NIH has partnered with an international consortium that includes the British-based Wellcome Trust, as well as Britain’s Medical Research Council and Department for International Development to test the same NIAID/GSK monovalent vaccine candidate. The vaccine candidate will be tested among 60 healthy volunteers at the University of Oxford in England and among 40 healthy volunteers in Mali by the University of Maryland School of Medicine Center for Vaccine Development and its Center for Vaccine Development in Mali (a joint enterprise of the University of Maryland School of Medicine and the Ministry of Health of Mali). Additionally, the vaccine candidate is expected to be tested among 40 healthy volunteers in Gambia after approval from the relevant authorities."
http://www.nih.gov/news/health/aug2014/niaid-28.htm
*FAIR USE*